AUTHOR=Fernández-Ruiz Mario , Membrillo-Solbes Pilar , Menéndez-Rodríguez Laura , Pérez-Junquera Paula , Rodríguez-Goncer Isabel , Ruiz-Merlo Tamara , Pérez-Jacoiste Asín María Asunción , López-Medrano Francisco , González Esther , Sandino Justo , San Juan Rafael , Andrés Amado , Aguado José María , Redondo Natalia TITLE=Human microRNA hsa-miR-125a-5p as biomarker for predicting late CMV infection in high-risk kidney transplant recipients JOURNAL=Transplant International VOLUME=Volume 39 - 2026 YEAR=2026 URL=https://www.frontierspartnerships.org/journals/transplant-international/articles/10.3389/ti.2026.17587 DOI=10.3389/ti.2026.17587 ISSN=1432-2277 ABSTRACT=Available strategies for predicting late-onset cytomegalovirus (CMV) infection in high-risk (seropositive donor/seronegative recipient [D+/R-]) kidney transplant recipients (KTRs) are suboptimal. We have previously shown that the expression level of human microRNA hsa-miR-125a-5p informs on the risk of CMV reactivation in seropositive (R+) KTRs. In the present work we assessed the predictive role of this microRNA in 50 consecutive D+/R- KTRs that received a 6-month course of valganciclovir prophylaxis. hsa-miR-125a-5p levels were measured by quantitative PCR in whole-blood samples obtained at the time of valganciclovir discontinuation. The cumulative incidence of late CMV infection through post-transplant month 12 was 46.0%. Patients who developed late CMV infection exhibited lower relative hsa-miR-125a-5p expression than those who remained free from this event (ΔCt values: 7.5 ± 1.3 vs. 6.7 ± 0.7, respectively; P-value = 0.005). The area under the receiver operating characteristic curve for predicting late CMV infection was 0.718 (95% confidence interval [CI]: 0.559–0.877). After multivariable adjustment, lower hsa-miR-125a-5p expression (ΔCt >7.623) was independently associated with the occurrence of late CMV infection (adjusted hazard ratio: 5.63; 95% CI: 2.28–13.91; P-value < 0.001). In conclusion, the relative expression of hsa-miR-125a-5p is useful to stratify the risk of late CMV infection in high-risk D+/R- KTRs.